Company profile
ALKERMES PLC.
NASDAQ:ALKSBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ARIPIPRAZOLE LAUROXIL | phase4 | — | 8 | no active trials |
| SAMIDORPHAN | phase3 | — | 9 | active |
| METHYLSAMIDORPHAN CHLORIDE | phase2 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (78)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03963973 | phase1 | terminated | 2019-05-16 | 2020-01-22 | Alkermes, Inc. | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 |
| NCT02272764 | phase1 | completed | 2014-10-01 | 2014-11-01 | Alkermes, Inc. | A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers |
| NCT02545439 | phase1 | completed | 2015-07-01 | 2015-10-01 | Alkermes, Inc. | A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers |
| NCT03610048 | phase3 | terminated | 2018-08-09 | 2020-05-01 | Alkermes, Inc. | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) |
| NCT02141399 | phase3 | completed | 2014-05-01 | 2017-11-20 | Alkermes, Inc. | A Long-Term Safety Study of ALKS 5461 |
FDA applications (0)
No records yet.